ACLY and prostate cancer: Similarly to SLC25A1, ACLY is significantly elevated in a variety of cancers, including melanoma (Guo et al, 2020), hepatocellular carcinoma (Gu et al, 2021), lung cancer (Lin et al, 2013), prostate cancer (Li et al, 2019), and breast cancer (Adorno-Cruz et al, 2021).